Caxton Associates LLP Acquires New Position in Solventum Corporation $SOLV

Key Points

• Caxton Associates LLP has acquired a new stake in Solventum Corporation (NYSE: SOLV), purchasing 50,000 shares valued at approximately $3.8 million.
• Several institutional investors increased their positions in Solventum, with Trian Fund Management L.P. raising its holdings by 18.8% to own over 8.4 million shares.
• Wall Street analysts are optimistic about Solventum, with Piper Sandler and Morgan Stanley upgrading their ratings and price targets, indicating a consensus target price of $85.75 for the stock.

Caxton Associates LLP bought a new position in shares of Solventum Corporation (NYSE:SOLV - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 50,000 shares of the company's stock, valued at approximately $3,802,000.

Several other institutional investors have also recently made changes to their positions in the business. Jones Financial Companies Lllp raised its holdings in shares of Solventum by 3,484.6% during the first quarter. Jones Financial Companies Lllp now owns 120,656 shares of the company's stock worth $9,175,000 after purchasing an additional 117,290 shares during the last quarter. Philosophy Capital Management LLC raised its holdings in shares of Solventum by 49.2% during the first quarter. Philosophy Capital Management LLC now owns 310,066 shares of the company's stock worth $23,577,000 after purchasing an additional 102,286 shares during the last quarter. Gotham Asset Management LLC raised its holdings in shares of Solventum by 14.9% during the first quarter. Gotham Asset Management LLC now owns 219,259 shares of the company's stock worth $16,672,000 after purchasing an additional 28,504 shares during the last quarter. Banque Transatlantique SA grew its position in Solventum by 9,219.8% during the first quarter. Banque Transatlantique SA now owns 59,274 shares of the company's stock valued at $4,165,000 after buying an additional 58,638 shares during the period. Finally, Adage Capital Partners GP L.L.C. grew its position in Solventum by 25.1% during the first quarter. Adage Capital Partners GP L.L.C. now owns 134,622 shares of the company's stock valued at $10,237,000 after buying an additional 27,000 shares during the period.

Analyst Ratings Changes

Several analysts recently commented on SOLV shares. Morgan Stanley upgraded shares of Solventum from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Jefferies Financial Group started coverage on shares of Solventum in a research report on Thursday. They set a "hold" rating and a $80.00 price target on the stock. Argus upgraded shares of Solventum from a "hold" rating to a "buy" rating and set a $90.00 price target on the stock in a research report on Tuesday, July 1st. Piper Sandler restated an "overweight" rating and set a $94.00 price target (up previously from $87.00) on shares of Solventum in a research report on Friday, August 8th. Finally, Wall Street Zen lowered shares of Solventum from a "strong-buy" rating to a "buy" rating in a research report on Tuesday. Four analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $85.11.

Solventum Price Performance

Shares of NYSE SOLV traded down $0.47 during mid-day trading on Friday, reaching $73.32. The company's stock had a trading volume of 1,572,089 shares, compared to its average volume of 1,079,221. The stock has a market capitalization of $12.71 billion, a P/E ratio of 33.95, a P/E/G ratio of 2.91 and a beta of 0.53. Solventum Corporation has a 1-year low of $60.70 and a 1-year high of $85.92. The stock has a 50-day moving average of $73.18 and a two-hundred day moving average of $72.73. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company had revenue of $2.16 billion during the quarter, compared to analysts' expectations of $2.12 billion. During the same quarter in the prior year, the company earned $1.56 EPS. Solventum's revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.